Primary hypertension in a postoperative paraganglioma patient: A case report

Jian-Hui Wei, Hai-Li Yan

Jian-Hui Wei, Hai-Li Yan, Department of Vasculocardiology, Sanmenxia Central Hospital, Sanmenxia 472000, Henan Province, China

Corresponding author: Hai-Li Yan, Doctor, Department of Vasculocardiology, Sanmenxia Central Hospital Middle, Western Xiaoshan Road, Hubin District, Sanmenxia 472000, Henan Province, China. lbyanhaili@163.com

Abstract

BACKGROUND
Primary hypertension is a common clinical disease. Pheochromocytoma and paraganglioma is a rare cause of secondary hypertension. The diagnosis of the latter is still difficult, and the relationship between the two is not clear. The successful diagnosis of this case confirmed that standardized etiological investigation of secondary hypertension is necessary, contributes to the accurate diagnosis of rare diseases, and is conducive to the formulation or optimization of treatment plans. It shows an example of the coexistence of primary hypertension and secondary hypertension.

CASE SUMMARY
The patient was a 54-year-old male and was hospitalized with high blood pressure for 4 years. The patient’s blood pressure was measured at 150/100 mmHg during physical examination 4 years ago and had no paroxysmal or persistent elevated blood pressure, no typical triad of headache, palpitation, and sweating, without postural hypotension. After taking nifedipine sustained release tablets intermittently, the blood pressure did not meet the standard. Physical examination revealed blood pressure of 180/120 mmHg. There was no abnormality in cardiopulmonary and abdominal examination. The results of blood and/or urinary catecholamines/metanephrine and normetanephrine before and after operation were normal. Fundus examination revealed retinal arteriosclerosis in both eyes. There was a history of paraganglioma diagnosed by pathology after retroperitoneal tumor resection, a family history of hypertension, and a history of passive smoking. The clinical diagnosis was subclinical paraganglioma, primary hypertension, and hypertensive fundus lesions. The patient’s blood pressure was regulated, blood lipid was reduced, and anti-inflammatory, and symptomatic support were given. After treatment, the blood pressure was stable and up to standard without discomfort symptoms.

CONCLUSION
Subclinical paraganglioma and primary hypertension can coexist. The holistic thinking in clinical practice is helpful to the early diagnosis of rare diseases.

Key Words: Paraganglioma; Primary hypertension; Secondary hypertension; Diagnosis and Differential diagnosis; Genetic; Case report

INTRODUCTION
Paraganglioma (PGL) is a rare cause of secondary hypertension that is manifested as a hypertensive crisis and easily leads to target organ damage. The reported prevalence of pheochromocytoma and paraganglioma (PPGL) is 0.2%–0.6%[1], with an incidence closely related to a germline gene mutation [2]. Surgery is the first option after diagnosis, resulting in a generally normal postoperative blood pressure. In this study, we present our findings on a confirmed case of combined postoperative PGL and primary hypertension.

CASE PRESENTATION
Chief complaints
A 54-year-old male had high blood pressure for 5 mo.

History of present illness
The patient’s blood pressure was 186/100 mmHg at a physical examination 5 mo ago without discomfort. However, taking a 20 mg nifedipine sustained-release tablet once daily did not normalize his blood pressure. He had stopped the medication 3 mo prior to the time of admission. Since the disease onset, he had maintained a good diet and slept without snoring.

History of past illness
He had a history of PGL resection (Figure 1) and postoperative pathological diagnosis of PGL (Figure 2).

Personal and family history
He had a history of passive smoking, and family history of hypertension, but no PPGL.

Physical examination
The physical examination at admission revealed a body temperature of 36.4 °C, pulse of 86 beats/min, breathing of 18 breaths/min, blood pressure of 188/108 mmHg, waist circumference of 96 cm, body mass index of 27.8 kg/m², clear mind, good spirit, and no murmur in neck and umbilical blood vessels. No abnormality was detected in the heart, lungs, and abdomen. No edema was found in both lower limbs, and positive nervous system signs were observed.

Laboratory examinations
Laboratory examinations revealed normal macrobiochemical parameters, thyroid function, parathyroid...
Figure 1 Computed tomography scan of paraganglioma. Performed on September 1, 2016: 64-slice computed tomography plain scan + enhanced scan (arrow). A mass of approximately 84 mm × 61 mm (right and left × back and forth) was observed below the left renal artery and vein, the abdominal aorta, the left psoas major muscle and the front of the left kidney. The edge was smooth, with an uneven density. The plain scan computed tomography value was within 17–41 HU. The arrow indicates the location, shape and size of the mass.

Figure 2 Histopathological features of paraganglioma. The tumor represents characteristic nest-like structure (arrow, hematoxylin and eosin × 40). The physician who completed the pathological diagnosis was the chief physician, who had been engaged in pathological diagnosis for 31 years. The arrow refers to the typical pathological feature of paraganglioma - nest-like structure.

hormone levels, cortisol and adrenocorticotrophic hormone levels, and rhythm as well as normal prolactin, antinuclear antibody spectrum, and 24-h urine protein levels. Blood aldosterone and renin were determined by chemiluminescence measurements (11.31). Metanephrine was 31.9 ng/L (reference range < 96.60 ng/L), detected by liquid chromatography-tandem mass spectrometry. Normetanephrine was 68.9 ng/L (reference range < 163.00 ng/L).

**Imaging examinations**

Adrenal and renal artery computed tomography: Bilateral adrenal hyperplasia and right renal artery stenosis. Brain magnetic resonance imaging and chest, abdomen, and pelvic computed tomography were normal.

**FINAL DIAGNOSIS**

(1) Postoperative PGL; and (2) Primary hypertension with hypertensive retinopathy stage 2.
TREATMENT
Felodipine sustained-release tablet of 5 mg was administered once daily combined with olmesartan/hydrochlorothiazide tablet of 20 mg/12.5 mg once daily.

OUTCOME AND FOLLOW-UP
The patient had no symptoms. At the last follow-up examination on April 23, 2021, the blood pressure was normal and stable.

DISCUSSION
Hypertension was defined as systolic blood pressure ≥ 140 mmHg and/or diastolic pressure ≥ 90 mmHg measured three times on a different day in the absence of antihypertensive medications. Secondary hypertension refers to hypertension caused by certain diseases or causes, accounting for about 5% of all hypertension, is characterized by endocrine dysfunction, such as primary aldosteronism. PGL patients, accounting for 15%–20% of all PPGL cases, have normal blood pressure without symptoms. They are distributed in the abdomen, chest, pelvic, neck, and brain tissue, especially in the retroperitoneum. A malignant tendency of PGL development has been reported, with a malignant transformation rate of 24%–50%.

PGL patients, accounting for 15%–20% of all PPGL cases, have normal blood pressure without symptoms. They are distributed in the abdomen, chest, pelvic, neck, and brain tissue, especially in the retroperitoneum. A malignant tendency of PGL development has been reported, with a malignant transformation rate of 24%–50%.

PGL patients, accounting for 15%–20% of all PPGL cases, have normal blood pressure without symptoms. They are distributed in the abdomen, chest, pelvic, neck, and brain tissue, especially in the retroperitoneum. A malignant tendency of PGL development has been reported, with a malignant transformation rate of 24%–50%.

The blood metanephrine was normal, and only the abdominal computed tomography revealed a left retroperitoneal mass. Importantly, postoperative pathological diagnosis of PGL should be differentiated from adrenocortical eosinophilic and low-grade neuroendocrine tumors.

PGL is curable secondary hypertension in which resection is to be performed after the diagnosis, which results in achieving normal postoperative blood pressure. This case completely differed from PPGL, with symptoms and positive examination results. It had high concealment, with no PPGL triad of headache, palpitation, sweating, and hypertension, and the specific marker of blood metanephrine was normal. The increase in the blood pressure occurred 3 years after the PGL operation.

Differential diagnosis and screening of PGL metastasis were performed based on the specific medical history, clinical manifestations, etiology of secondary hypertension, distribution of PGL, and the site of metastasis. Renal parenchymal hypertension, renovascular hypertension, primary aldosteronism, sleep apnea hypopnea syndrome, hypercortisolism, pituitary tumors, thyroid and parathyroid dysfunction, pharmacogenic hypertension, and connective tissue disorders, such as vasculitis and systemic sclerosis, were excluded.

No recurrence or metastasis was observed in PGL, and the diagnosis of primary hypertension was clear.

Meanwhile, because of the lack of family history of hypertension, middle age, short course of disease, mild target organ damage, and PGL history, this case was different from the commonly known primary hypertension. High blood pressure occurred after the PGL operation. The diagnosis of the combination of postoperative PGL and primary hypertension was confirmed by recurrence and metastasis screening. After reviewing the literature, the diagnosis of postoperative PGL was clear albeit rare in clinical practice. No related report was available of subclinical postoperative PGL and primary hypertension, and thus we had to make the differential diagnosis. This case has deepened the clinician’s understanding that primary hypertension and secondary hypertension can coexist. In the era of precision medicine, holistic thinking is helpful to the diagnosis and treatment of diseases.

CONCLUSION
Despite its rare occurrence, postoperative PGL patients can develop primary hypertension. The screening, diagnosis, and differential diagnosis of PPGL should be performed in cases with adrenal incidentaloma, retroperitoneal mass, or carotid body tumor. Pathological diagnosis is the gold standard for PPGL diagnosis.

FOOTNOTES
Author contributions: Wei JH conceived the idea, designed the experiments, and interpreted the data; Wei JH and Yan HL performed the experiments, analyzed the data, and wrote the manuscript; all authors reviewed and approved the manuscript.
Supported by the Key Project of Medical Science and Technology of Henan Province, No. LHGJ20200923; and the Sanmenxia Science and Technology Bureau Science and Technology Development Program Science and Technology Benefit the People Project, No. 201906036.

Informed consent statement: All experiments were performed in compliance with the ethical standards formulated in the Helsinki Declaration of 1964. The study was approved by the Sanmenxia Central Hospital. Informed consent was obtained from the patient.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

CARE Checklist (2016) statement: The authors have read the CARE Checklist(2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: China

ORCID number: Jian-Hui Wei 0000-0002-2802-2418; Hai-Li Yan 0000-0002-4068-5847.

S-Editor: Xing YX
L-Editor: Filipodia
P-Editor: Xing YX

REFERENCES

1. Endocrinology CSo, Association CM. Expert consensus on the diagnosis and treatment of pheochromocytoma and paraganglioma (2020). Zhonghua Neifenmi Daixie Zazhi 2020; 36: 737-750 [DOI: 10.3760/cma.j.cn311282-20200629-00482]
2. Zhang F, Kan W. New advances in genomics of pheochromocytomas and paragangliomas. World J Clin Oncol 2018; 45: 969-972 [DOI: 10.1177/1000-8179.2018.18.724]
3. Chen X, Cui Z, Lin J. Comment and key-points translation of International Society of Hypertension global hypertension practical guideline. Zhongguo Xixue Qianyan Zazhi 2020; 12: 54-60 [DOI: 10.12037/YXQY.2020.05-08]
4. Ge J, Xu Y, Wang C. People's Medical Publishing House. J Intern Med 2017; 310: 711-712 [DOI: 10.1007/978-981-32-9178-2_9]
5. Tong A, Li H. Neuroendocrine Neoplasias Related to Hypertension: Current Status and Progress. Xiehe Yixue Zazhi 2020; 11: 361-364 [DOI: 10.3969/j.issn.1674-9081.2020.04.001]
6. Wang L, Ma R, Chang H. Clinicopathological analysis of adrenal pheochromocytoma. Linchuang Zhongliuxue Zazhi 2020; 25: 257-260 [DOI: 10.3969/j.issn.1674-9081.2020.03.012]
7. Eisenhofer G, Prejbisz A, Petzsch M, Pamporaki C, Masjuk J, Rogowski-Lehmann N, Langton K, Tsourdi E, Pęczkowska M, Fiedler S, Deutschshein T, Megerle F, Timmers HJLM, Sinnott R, Beuschlein F, Fassnacht M, Januszewicz A, Lenders JW. Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma vs Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. Clin Chem 2018; 64: 1646-1656 [PMID: 30097498 DOI: 10.1373/clinchem.2018.291369]
8. Li N. Clinical diagnosis and treatment of secondary hypertension. Zhonghua Gaoxueya Zazhi 2014; 22: 516-518 [DOI: 10.1201/b17072-40]
9. Committee CHPaTGR, (China) HA, Cardiology HPCoCMDAoCAo, Exchanges HBoCAftPoIH, Society HBoCG. Chinese guidelines for the management of hypertensionWriting Group of 2018. Zhongguo Xinxueguan Zazhi 2019; 24: 24-56 [DOI: 10.3969/j.issn.1009-816X.2019.01.001]
